SHP-654

N/A

Report date: 2024/01/02 20:03:52

Base Information

Drug NameSHP-654
Drug Alias Name第八因子基因疗法八因子基因疗法SHP-654BAX-888
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adeno-associated virus vector > AAV8 vector
Mechanisms of ActionBlood coagulation pathway activationCoagulation factor VIII modulatorsFactor VIII gene transference
TargetsCoagulation factor VIII
Therapy Area/IndicationsHemophilia A
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesHungaryAustria +[6] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesShire PharmaceuticalsBaxalta Incorporated
China Registration ClassN/A

Develop Information

Active CompaniesBaxalta Innovations GmbhBaxalta IncorporatedTakeda Development Center Americas Inc
Inactive CompaniesN/A
Active IndicationsHemophilia A
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A